Tachmed aims to Leap ahead with lab move

A pioneering medtech company is gearing up for its next stage of growth after relocating to a new science incubator designed to accelerate innovation and commercial development.

Tachmed has moved into Leap, a newly opened lab incubator at ARC West London, as it prepares to advance development of its AI-powered diagnostic technology. 

Founded in 2018 by Paul Christie and Lord Maxwell Beaverbrook, the company is developing TachShield, a low-cost device designed to enable rapid, self-administered testing for a wide range of chronic and infectious conditions.

Scheduled to launch in 2026, TachShield is intended to deliver results within seconds, identifying markers linked to conditions such as cardiovascular disease, obesity and inflammatory illnesses, alongside viruses including flu and Covid-19.

From its new base near Hammersmith, Tachmed will focus on finalising product development ahead of TachShield’s launch in 2026, with ambitions to reduce healthcare waiting times and costs through earlier diagnosis and improved access to testing.

Paul, chief executive of Tachmed, said: “Moving into Leap marks a major milestone for Tachmed as we accelerate the final phase of development for TachShield. 

“ARC West London provides the ideal environment for innovation, collaboration and scale, and being surrounded by world-class innovators and leading clinical and academic institutions will be invaluable as we move towards delivering a new standard of accessible, AI-enhanced diagnostics.”

Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →

Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.